ACVR1C

ACVR1C
Identifiers
Aliases ACVR1C, ACVRLK7, ALK7, activin A receptor type 1C
External IDs OMIM: 608981 MGI: 2661081 HomoloGene: 26724 GeneCards: ACVR1C
Orthologs
Species Human Mouse
Entrez

130399

269275

Ensembl

ENSG00000123612

ENSMUSG00000026834

UniProt

Q8NER5

Q8K348

RefSeq (mRNA)

NM_145259
NM_001111031
NM_001111032
NM_001111033

NM_001033369
NM_001111030

RefSeq (protein)

NP_001104501.1
NP_001104502.1
NP_001104503.1
NP_660302.2

NP_001104500.1

Location (UCSC) Chr 2: 157.53 – 157.63 Mb Chr 2: 58.27 – 58.36 Mb
PubMed search [1] [2]
Wikidata
View/Edit HumanView/Edit Mouse

The activin A receptor also known as ACVR1C or ALK-7 is a protein that in humans is encoded by the ACVR1C gene.[3] ACVR1C is a type I receptor for the TGFB family of signaling molecules.[3]

ACVR1C transduces signals of Nodal. Nodal binds to ACVR2B and then forms a complex with ACR1C. These go on to recruit the R-SMADs SMAD2 or SMAD3.[4]

Upon ligand binding, type I receptors phosphorylate cytoplasmic SMAD family transcription factors, which then translocate to the nucleus and interact directly with DNA or in complex with other transcription factors.[3]

References

  1. "Human PubMed Reference:".
  2. "Mouse PubMed Reference:".
  3. 1 2 3 Bondestam J, Huotari MA, Morén A, Ustinov J, Kaivo-Oja N, Kallio J, Horelli-Kuitunen N, Aaltonen J, Fujii M, Moustakas A, Ten Dijke P, Otonkoski T, Ritvos O (2001). "cDNA cloning, expression studies and chromosome mapping of human type I serine/threonine kinase receptor ALK7 (ACVR1C)". Cytogenet. Cell Genet. 95 (3–4): 157–62. doi:10.1159/000059339. PMID 12063393.
  4. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS (July 2002). "SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7". Mol. Pharmacol. 62 (1): 65–74. doi:10.1124/mol.62.1.65. PMID 12065756.

External links

Further reading

This article is issued from Wikipedia - version of the 11/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.